by the ESMO Guidelines Committee, ERN PaedCan and EURACAN:
ES has an incidence of 0.3 per 100 000 per year [5] , and it is even rarer in the African and Asian population. The genetic basis for the difference between ethnical groups has been recently linked to a common genomic germline variant, which extends a microsatellite, thereby facilitating the binding of the EWSR1-FLI1 chimeric protein to the EGR2 gene locus, leading to higher expression of the transcription factor early growth response 2 (EGR2) and increased susceptibility to ES [6] . The most common ES primary sites are the extremity bones (50% of all cases), followed by pelvis, ribs and vertebra. However, any bone can potentially be affected, and a soft-tissue origin is also possible, especially in adults (30% of cases).
Chordomas are even rarer compared to other subtypes, with an incidence of ∼0.5 per million per year [7] .
High-grade spindle/pleomorphic sarcomas of bone: spindle cell sarcomas of bone are a heterogeneous group of primary malignant bone tumours that do not fulfil the histological criteria for a diagnosis of osteosarcoma, chondrosarcoma or Ewing's sarcoma [8] .
Giant cell tumour of bone is a benign intramedullary bone tumour composed of mononuclear cells and osteoclast-like multinucleated giant cells, with a variable and unpredictable potential for aggressive growth. It represents approximately 5% of primary bone tumours and about 15%-20% of benign bone tumours [9] .
Diagnosis and pathology / molecular biology
The medical history should focus on characteristic symptoms such as duration, intensity and timing of pain. The presence of persistent non-mechanical bone pain, predominantly at night, should prompt a radiological assessment. Swelling and functional impairment can be present if the tumour has progressed through the cortex and distended the periosteum, but they are often later signs. The differential diagnosis of a bone sarcoma includes osteomyelitis, benign tumours and bone metastases, all of which outnumber primary bone sarcomas [10] [11] [12] [13] . The diagnosis can be strongly oriented by patient age. For patients ˂ 5 years old, a destructive bone lesion could be interpreted predominantly as either metastatic neuroblastoma or Langerhans cell histiocytosis (LCH). For patients aged ≥ 5 years old, the likelihood of a primary bone sarcoma is higher. In adult patients, after 40 years of age, bone metastases and myeloma will be the most common diagnoses [13] .
Conventional radiograph in two planes is the first radiological investigation. When the diagnosis of malignancy cannot be excluded with certainty on radiographs, the next step should be magnetic resonance imaging (MRI) of the whole compartment with adjacent joints, which is regarded today as the best modality for local staging of extremity and pelvic tumours [14] . Computed tomography (CT) may provide additional information by allowing a better visualisation of calcifications, periosteal bone formation and cortical destruction. It is generally the imaging modality of choice of other primary sites.
All patients with a bone lesion which is likely to be a primary malignant bone tumour on a radiological basis should be referred to a bone sarcoma centre or to an institution belonging to a specialised sarcoma network [14] [15] [16] . Children and adolescents should be referred to centres which in addition provide age-specific expertise. The biopsy and the pathological diagnosis require expertise in the field and should be discussed in a multidisciplinary setting.
The biopsy of a suspected primary malignant bone tumour should be carried out at the reference centre by either the surgical team who will carry out the definitive tumour resection or by a dedicated interventional radiologist [15] [16] [17] [18] . In most patients, a coreneedle biopsy, taken under imaging control, can be an appropriate alternative to open biopsy. Contamination of surrounding tissue should be minimised, and adequate multiple sampling of representative areas must always be provided. To ensure that the tissue is representative of the tumour, X-rays of the biopsy location are recommended, and, in some circumstances, a frozen section may be required for diagnosis in some cases and recommended for research purposes. If osteomyelitis is a differential diagnosis, samples should be sent for microbiological culture. If required, an open biopsy should be carried out using a longitudinal incision. In aggressive and malignant tumours of bone, the biopsy tract and the channels through which drains have been placed must be considered to be potentially contaminated and must later be removed, together with the resection specimen, in an effort to minimise the risk of a local recurrence. Therefore, biopsy tracts should be clearly marked by means of a small incision or an ink tattoo to ensure that the location is recognised at the time of the definitive procedure. In case of spinal column involvement, laminectomy or decompression should be avoided unless necessary to relieve spinal cord compression, and tissue sampling must be carried out whenever a bone sarcoma is suspected.
Samples must be interpreted by an experienced bone sarcoma pathologist, in collaboration with the radiologist, and discussed in a multidisciplinary team. The request form should be completed with all details that might be relevant for diagnosis, including patient's age, the site of the tumour, radiological findings, if there are multiple lesions, family history and, for surgical specimens, preoperative treatments.
With the increasing capability for accurate molecular diagnosis and next-generation sequencing (NGS) technologies, samples should be quickly submitted for pathological assessment. The collection of fresh frozen tissue is strongly encouraged, to enable molecular diagnostics. As an alternative, decalcification in ethylenediaminetetraacetic acid (EDTA) instead of formic acid can be considered. Tumour imprints (touch preps) are used by some, but not all expert institutions: they might be useful for tumourspecific translocation by fluorescent in situ hybridisation (FISH) in some institutions.
Informed consent for tumour banking should be routinely sought as for all rare malignancies, enabling later analyses for research, depending on local regulations.
Similarly, a further option is to establish primary cell cultures for cytogenetics and other studies, such as patient-derived xenografts within research protocols with informed consent.
The nature of the bone specimen received for pathology reporting should be recorded, i.e. needle biopsy, curettage or excision (e.g. segmental resection, limb salvage amputation, or another complex resection, such as a hemipelvectomy). It is usually necessary to decalcify the bone tumour biopsy using specific standard operating procedures. The histological features of the tumour should be described and the tumour type (and subtype) specified according to the most recent version of the World Health Organization (WHO) Classification [19] . The results of relevant ancillary investigations (e.g. immunohistochemistry or molecular assessments) should be accurately recorded [16] . Molecular diagnostic techniques currently available include FISH, RT-PCR and NGS technologies. Examples include translocation detection in ES and mesenchymal CS, isocitrate dehydrogenase (IDH1 and IDH2) mutations in conventional chondrosarcoma and MDM2 amplification in parosteal and intramedullary low-grade osteosarcoma [4] . Photographs should be taken of the intact specimen and of the tumour slabs after sawing. A complete, representative slab of the tumour, usually in the longitudinal axis as guided by the radiological images, should be embedded for microscopy in a grid manner. This is especially relevant after neoadjuvant chemotherapy to assess response. The tumour should be coded using Systematic Nomenclature of Medicine (SNOMED) or International Classification of Diseases for Oncology (ICD-O) codes.
Staging and risk assessment
All cases of suspected bone tumours should be formally discussed in a multidisciplinary team in a reference centre with the radiologist who has interpreted the imaging, the pathologist who has reviewed the biopsy material, the surgeon, the radiation and the medical and/or paediatric oncologist. The output of the multidisciplinary discussion must be recorded, in order to minimise the risk of errors in diagnosis, staging, risk assessment and treatment.
Several staging systems for bone tumours are in use [20] [21] [22] [23] . However, none of them is perfect or generally accepted. Generally, tumour burden (volume) and the presence of detectable metastases are the two main factors that are taken into consideration in the clinical staging of these diseases. General staging should be carried out to assess the extent of distant disease, including bone scintigraphy, chest radiographs and CT [24] . Whole-body MRI and positron emission tomography (PET)-CT or PET-MRI are increasingly utilised for staging (including skip bone lesions) [25] .
Additional appropriate imaging studies and biopsies can be taken from suspicious sites, as the exact staging of the disease has an impact on treatment and outcome.
No specific laboratory tests for the diagnosis of bone sarcoma are routinely available.
Baseline serum analysis in ES and OS should include alkaline phosphatase (AP) and
lactate dehydrogenase (LDH) given their proven prognostic value [26] [27] [28] . Prognostic features also include clinical presentation: a pathological fracture may lead to the dissemination of tumour cells into surrounding tissues and increase the risk of local recurrence. In cases of fracture, internal fixation is contraindicated as it disseminates the tumour further into both bone and soft tissues and increases the risk of local recurrence. External splintage is recommended.
Chemotherapy can result in renal, cardiac and auditory dysfunction. Before starting the treatment, baseline renal function testing, assessment of cardiac function [left ventricular ejection fraction (LVEF)] and audiogram (in the case of platinum derivatives) should be carried out. Sperm storage is recommended for male patients of reproductive age. For female patients, a fertility physician is routinely consulted about potential ovarian sampling and cryopreservation in some countries, but not in all, reflecting a limited scientific knowledge on gonadotoxic effects of the different chemotherapy used and a variability of healthcare policies across nations [29] .
Treatment (locoregional and advanced disease)
Given the rarity of the disease and the complexity of management, the accepted standard for bone sarcomas is treatment at reference centres and/or within reference networks able to provide access to the full spectrum of care and age-specific expertise [III, A]. In these centres/networks, therapy is usually given within either the framework of prospective, often collaborative, clinical studies or established treatment protocols.
In the case of high-grade osteosarcoma, ES or pleomorphic sarcoma, following biopsy proven-diagnosis, primary chemotherapy is indicated.
Osteosarcoma
Osteosarcoma usually arises in the metaphysis of a long bone, most commonly around the knee in children and adolescents. Involvement of the axial skeleton and craniofacial bones is primarily observed in older patients. High-grade osteosarcoma frequently metastasises, the lung being the most frequent metastatic site by far, Curative treatment of high-grade osteosarcoma consists of chemotherapy and surgery [II, A]. Compared with surgery alone, multimodal chemotherapy treatment of highgrade localised osteosarcoma increases disease-free survival probability from 10%-20% to > 60%. In general, chemotherapy is administered before and after surgery, although a formal proof that giving chemotherapy preoperatively improves survival is lacking. The extent of histological response to preoperative chemotherapy predicts survival [26] [27] [28] 30] .
Low-grade central and parosteal osteosarcoma are malignancies with a lower metastatic potential, which are treated by surgery alone [IV, B]. Although chemotherapy has been used for periosteal osteosarcomas, no benefit for chemotherapy was shown in two retrospective analyses [31, 32] , and its use is not routinely recommended in this setting [IV, D] .
Surgery should be carried out by a surgical team familiar with the wide range of surgical reconstructive options. Paediatric and adolescent patients need to be treated by surgeons with great experience in the field of paediatric bone tumours, including age-specific reconstruction challenges, such as the reconstruction of growing bones.
The goal of surgery is to safely remove the tumour and yet preserve as much function as possible, striving to obtain microscopically clear surgical margins [30] . Most patients should be considered candidates for limb salvage. Pathological fracture does not necessarily necessitate an amputation. In chemosensitive tumours, primary neoadjuvant chemotherapy can be used with the expectation that it will allow the fracture haematoma to contract and allow subsequent resection of the tumour and the involved soft tissues [33] .
Doxorubicin, cisplatin, high-dose methotrexate (HD-MTX) and ifosfamide have antitumour activity in osteosarcoma [I, A] [34] [35] [36] [37] . Doxorubicin, cisplatin and HD-MTX (MAP) are most frequently used as the basis of treatment in children and young adult patients [31] ; however, HD-MTX can be difficult to manage in adults ˃ 25 years old. In older patients, regimens combining doxorubicin, cisplatin and ifosfamide without HD-MTX can also be used in these patients [III, B] . These drugs should be administered with adequate supportive care by experienced paediatric oncologists or medical oncologists at reference institutions with appropriate infrastructure and a multidisciplinary treatment approach [35] . Most current protocols include a period of preoperative chemotherapy, to facilitate local surgical treatment and to allow the assessment of tumour response [38, 39] . The EURAMOS 1 prospective trial aimed to establish whether pegylated interferon alpha-2b (IFN2b), in addition to standard MAP chemotherapy given postoperatively, could improve outcome in patients with good histological response to preoperative MAP. The results showed that many patients failed to start and complete interferon treatment, and there was no significant overall survival advantage [I, C] [40, 41] . Also, the study evaluated if altering postoperative chemotherapy in poor responders to preoperative systemic therapy might have any impact on outcome, and, again, no survival benefit was proven. In Innate immune-modulation has been attempted in OS with some agents, e.g.
interferon [35] and muramyl tripeptide. As described above, the use of interferon failed to show a survival advantage in patients with a good histological response to a MAPpreoperative regimen. Muramyl tripeptide added to postoperative chemotherapy was associated with a significant advantage in overall survival and a non-significant trend in event-free survival in one large randomised trial [II, C] [42, 43] . Muramyl tripeptide has been approved in Europe for patients < 30 years of age with completely resected localised osteosarcoma, but it is not reimbursed in all European countries. There is no consensus in the sarcoma community on the use of this drug, due to weaknesses in the data from the only trial currently available [42] . Further studies are needed to identify any subgroup of patients who could benefit from immune modifying agents.
Dynamic MRI is reliable to evaluate changes in tumour vascularity and to give additional information on tumour response to primary chemotherapy [44, 45] . Similarly, the value of diffusion MRI is currently under evaluation [45] .
In general, there is no indication for radiotherapy, but there are anatomical locations in which the possibility of complete surgical resection is limited. In these cases, after a multidisciplinary discussion, radiotherapy may be an option to try to extend the progression-free interval. This must be discussed in a multidisciplinary team beforehand and with the patient, and it should be made clear at the time of surgery that the goal is not an R0 resection [V, C]. New radiotherapy techniques (e.g. proton beam and carbon ion therapy) should be considered, particularly for unresectable primary tumours.
The multimodal treatment principles detailed above were generated in children, adolescents and young adults with high-grade central osteosarcoma, but also relate to adults [III, B] [46] . Adult patients may require tailored regimens, especially as far as HD-MTX is concerned, in particular for those aged > 40. Some studies have put a threshold of 25 to remove HD-MTX from the induction regimen [47] , while others included HD-MTX for older patients [48] . Doxorubicin plus cisplatin and/or ifosfamide are commonly used with age-adapted doses. Recently, the addition of zoledronic acid was tested in a randomised setting and failed to demonstrate an improvement in relapse-free or overall survival or histological response. Its use is, therefore, not
Primary metastatic osteosarcoma patients are treated with a curative intent following the same principles of non-metastatic osteosarcomas [49] . In fact, there are subsets of patients who can have a very similar prognosis to that of localised disease, provided surgical removal of all known metastatic deposits is achievable [III, B] [50] .
Approximately 25% of all patients with primary metastatic osteosarcoma and > 40% of those who achieve a complete surgical remission may become long-term survivors.
High-grade craniofacial osteosarcoma should be treated the same way as high-grade osteosarcoma of other locations, although prospective evidence is lacking due to the absence of selective clinical studies in this patient population [IV, B]. The use of PET monitoring is under investigation [51] . Radiotherapy, preferably within clinical studies, can be proposed when complete surgery is not feasible [IV, B]. The value of proton beam/carbon ion radiotherapy in this setting is currently under study. Adjuvant RT follows the same recommendations that for other sites (see above).
The management of recurrent osteosarcoma needs to take into account the timing of recurrences/metastases, the number of metastases and the metastatic sites. CT scan can over-and under-estimate the number of pulmonary metastases, but the recent results have improved with spiral CT. The treatment of recurrent osteosarcoma is primarily surgical in the case of isolated lung metastases. Complete removal of all metastases must be attempted [III, B], as the disease is otherwise almost universally fatal, while more than a third of patients with a complete second surgical remission survive for > 5 years [52] . Even patients with subsequent recurrences may be cured as long as recurrences are resectable, and repeated thoracotomies are often warranted [52] . For lung metastases, stereotactic radiotherapy, radiofrequency ablation or cryotherapy might be used as alternative options in patients unfit for surgery [IV, B] . Some groups also consider radiofrequency ablation [53, 54] and stereotactic radiotherapy [55] to be potential alternative local treatment options for small lung or bone metastases [53] [54] [55] .
The role of second-line chemotherapy for recurrent osteosarcoma is much less well defined. Treatment choice may take into account the prior disease-free interval, and Radiotherapy may have a role in palliation [61] . In general, despite second-line treatment, the prognosis of recurrent disease has remained poor, with a long-term post-relapse survival of < 20%.
Ewing sarcoma
ES is a small, blue, round cell tumour, periodic acid-Schiff positive and CD99 (MIC2)positive. All ES are high-grade tumours. They can arise both from bone, soft tissues or visceral sites, displaying the same behaviour in principle.
The definitive diagnosis is made by biopsy, providing sufficient material for conventional histology, immunohistochemistry, molecular pathology and biobanking.
Molecular biology studies have shown that almost all of these tumours share a common TET-ETS gene rearrangement involving the EWSR1 gene on chromosome 22 [46, 47] . In most cases, this involves a reciprocal translocation t(11;22)(q24;q12) [48] , but t(21;22)(q22;q12) [49, 50] , and others may also occur [t (7;22) translocations are other examples of recurrent molecular alterations found in these malignancies [66, 67] (see Table 1 ).
Current investigations have shown that tumour biology and prognosis of these tumours, which are probably different nosological entities rather than molecular variants actually differs from that of classical ES, making the diagnosis and identification of these cases mandatory. Since not all are recognised in routine, the patients presenting with these tumours are still treated within Ewing-like regimens. However, given the low incidence of these rare tumours, currently there is little evidence to support different approaches to their management. Inclusion in prospective registries is worthwhile (a EURACAN Domain 1 sarcoma project is underway for this purpose).
Although most ES tumours can be recognised with classical haematoxylin and eosin (H&E) stain and immunohistochemistry molecular confirmation is mandatory for the identification of the classical and distinct molecular subtypes as described above [ [27, [71] [72] [73] [74] [75] . Molecular structure of the EWSR1 fusion transcripts has not been shown to be of prognostic value with current treatment protocols.
Genomic analysis with the assessment of copy number variation has been shown to be of prognostic value [77, 78] . In addition, Stag2, TP53 and CDKN2A mutations confer poorer outcomes. With surgery or radiotherapy alone, i.e. without systemic treatments, 5-year survival was < 10%. With the currently recommended multimodal approaches including chemotherapy, 5-year survival is ∼60%-75% in localised and ∼20%-40% in metastatic disease, respectively, depending on metastatic sites and burden.
Current trials employ 3-6 cycles of initial combination chemotherapy after biopsy, followed by local therapy, and another 6-10 cycles of chemotherapy, usually applied Intralesional surgery must be avoided, as there is no benefit when compared with radiotherapy alone [73] . Change in the size of the soft tissue mass is easily evaluated on MRI and is a good predictor of tumour response [44, 45] . Dynamic MRI is not as reliable as in osteosarcoma [45] , as remaining small tumour foci may not be detected.
Sequential FDG-PET evaluation might be of additional value [87] . Patients with metastases at diagnosis are treated with the same treatment approach as patients with localised disease but have a worse prognosis. In patients with lung metastases, whole-lung irradiation may confer a survival advantage [II, C] [74, 75] .
The role of surgical resection of residual metastases is less well defined.
For patients presenting with extra-pulmonary metastases, survival is even worse (less than 20%) [88] . Chemotherapy is similar to that for localised disease but responses are less durable. Treatment of the primary tumour is often appropriate, especially in the presence of responding metastatic disease. There is no formal evidence either for or against high-dose chemotherapy in this situation, so that its uptake differs between centres. No randomised studies have been reported for this approach.
Recurrent ES, whether local or with distant metastases, is almost always fatal, even though further responses to chemotherapy are frequent and valuable. The only prognostic factor identified in relapsed patients seems to be time to relapse: patients relapsing later than 2 years from initial diagnosis have a better outcome [89] . 
High-grade spindle/pleomorphic sarcomas of bone
Pleomorphic sarcomas of bone comprise a diagnostically heterogeneous group of malignant tumours including undifferentiated pleomorphic sarcoma [8, 21] . They arise in a similar age group to chondrosarcoma, but the skeletal distribution is more like osteosarcoma. They typically present with pain and have a high incidence of fractures at presentation. They represent between 2% and 5% of primary bone malignancies.
Males are more frequently affected than females. An association with pre-existing disease (Paget's disease or bone infarct) or history of previous irradiation has been reported. It is not unusual for a spindle cell sarcoma to be found to be either a dedifferentiated chondrosarcoma or osteosarcoma after examining further different sections of the resection. Therefore, the diagnosis should be established in a multidisciplinary setting and IDH mutation analysis should be considered when the radiological images suggest a chondrosarcoma.
Pleomorphic sarcomas typically present in older patients with a lytic lesion in bone. In many, the differential diagnosis will be against metastases. are highly required. Radiotherapy may be considered in inoperable lesions. A global effort to collect these cases would be helpful to establish diagnostic and prognostic criteria as well as recommended treatments, for the whole group as well as for the different histologies.
Chondrosarcoma
Most chondrosarcomas arise as primary malignant tumours. The majority are lowgrade, locally aggressive, non-metastasising tumours (atypical cartilaginous tumour / chondrosarcoma grade I), rather than high grade (grades II-III) [17, 92] . Grade I chondrosarcomas can be labelled atypical cartilaginous tumour, as it is currently defined by the WHO 2013, since they usually do not metastasise [2] . Grade I chondrosarcomas may be treated with radiotherapy when located at critical sites such as the skull base. Most chondrosarcomas arise centrally in the metaphyseal region of long bones, but they can also develop in flat bones such as pelvis, rib and scapula.
High-grade chondrosarcoma frequently arises in the axial skeleton and long bones.
Chondrosarcoma can arise in pre-existing benign lesions such as enchondroma and osteochondroma. In these circumstances, they are referred to as secondary central chondrosarcoma and secondary peripheral chondrosarcomas, respectively. The majority of chondrosarcomas are of the conventional subtype, but rarer subtypes include mesenchymal and clear cell chondrosarcoma [93, 94] . In rare circumstances, conventional chondrosarcomas can 'dedifferentiate' into a very high-grade tumour with a dismal prognosis: the so-called dedifferentiated chondrosarcoma [93, 94] . Most chondrosarcomas are solitary, but they can occur as multiple lesions in syndromic patients with multiple osteochondromas and enchondromatosis.
Pain at the site of a cartilaginous lesion may be an indicator of malignancy. In the case of chondrosarcoma, a contrast-enhanced MRI can reveal high-grade areas. This provides a useful guide to the site of biopsy [95] . For large axial and pelvic chondrosarcoma, heterogeneity is common, and most lesions contain high-grade elements. The differentiation between benign enchondroma or osteochondroma and atypical cartilaginous tumour / chondrosarcoma grade I can be difficult, but can be aided by the use of dynamic contrast-enhanced MRI [96] . In the phalanges of the hands and feet, malignancy is extremely rare, but in the other long bones central cartilaginous lesions should be considered atypical cartilaginous tumour unless proven otherwise [93] .
Inoperable, locally advanced and metastatic high-grade chondrosarcomas have a poor prognosis [76, 77] . Prognosis depends on histological grade. However, histological classification is subject to variability in interpretation, with grade II and III chondrosarcomas often grouped together, even though there is a wide spectrum of outcome and heterogeneity of grade elements within tumours [75] . Also, grade I tumours (atypical cartilaginous tumours) are not necessarily curable in all cases, mainly due to problematic local recurrence or progression to high grade. In particular, dedifferentiated chondrosarcomas are aggressive and frequently metastasise [76] .
Assessing the grade of chondrosarcomas is difficult and discrepant diagnoses are common even among experts [92] . Atypical cartilaginous tumours are unlikely to There is a very high risk of local recurrence following excision of dedifferentiated chondrosarcoma, particularly in the presence of a pathological fracture. If wide margins cannot be reliably achieved with limb salvage, amputation should be considered.
The role of radiotherapy in chondrosarcoma is limited, but may be appropriate in highly selected cases or for palliation. Excellent outcomes have been reported for skull base chondrosarcomas with high-dose radiotherapy, including proton beam or carbon ion radiotherapy, achieving 80%-90% local control rates [101] .
With regard to chemotherapy, drugs active in sarcomas such as doxorubicin and ifosfamide may prove active in chondrosarcoma, especially in high-grade lesions [99, 102] . The activity of gemcitabine in combination with docetaxel has been reported [103] , and a potential role for mammalian target of rapamycin (mTOR) inhibitors in combination with cyclophosphamide has been suggested [IV, C].
Giant cell tumour of bone
Giant cell tumour (GCT) of bone is a rare [104] , locally aggressive tumour of the skeleton. GCT is classified in the intermediate category, as GCT can be aggressive and recurs locally in up to 50% of cases [9] . Soft tissue extension is significantly associated with the risk of local recurrence. Up to 5% of GCTs metastasise to the lungs, and transformation to a high-grade malignancy though debated, may occur in 1%-3% of patients. Giant cell tumours of bone contain mutations in the H3F3A gene (predominantly at the G34 position) which can be detected using mutation analysis or immunohistochemistry using mutation specific antibodies [104, 105] .
Treatment options include intralesional curettage with or without adjuvant or en bloc excision [IV, A]. These have been assessed in a few prospective studies [106] [107] [108] [109] .
Denosumab, a human monoclonal antibody to receptor activator of nuclear factor kappa B ligand (RANKL), known to be overexpressed in GCT, is standard treatment in unresectable or metastatic GCT [III, A] [110] . Its use in the neoadjuvant setting is debated and should be carried out exclusively in expert centres, and ideally within a clinical trial. There is increasing evidence that, if being used preoperatively and prior to curettage, surgery is best carried out after a few months of treatment, as otherwise extensive ossification may take place, making it difficult to define the extent of the lesion [V, C]. It can also be used in unresectable disease and rare metastatic disease.
In this setting, treatment interruption is usually followed by progression, so that treatment needs to be maintained [110] . Potential maxillar and skeletal side effects need to be monitored (osteonecrosis of the jaw, atypical fractures). The optimal schedule and duration of treatment with denosumab in surgically unsalvageable GCTs is still to be settled, and the possible long-term side effects are still largely unknown.
Radiotherapy can provide a satisfactory local control in GCT (5-year control rate of 80%) [109] . However, the use of radiotherapy can be associated with a risk of GCT transformation into a high-grade sarcoma and can make surgical resection challenging if required. Therefore, the use of radiotherapy in GCTs should always be discussed in a multidisciplinary setting and be limited to cases in which surgery leads to unacceptable morbidity and denosumab is ineffective or contraindicated [IV, D].
Chordoma
Chordomas are very rare tumours, arising from the remnants of the notochord into the sacrum (50%), skull base (30%) and mobile spine (20%). Extraskeletal cases have also been reported but are extremely rare.
Median age is 60 years, but skull base presentations can also affect a younger population, including children and adolescents. Chordoma is a low-grade but locallyinvasive malignancy. Dedifferentiated cases are observed in 5% of patients. The metastatic potential of chordoma is ∼30%. Metastases usually appear late in the natural history of the disease, mostly after local recurrence.
Chordoma prognosis is related more to local aggressiveness than to metastases.
Chordoma is a tumour showing notochordal differentiation. Brachyury is a transcription factor involved in notochord differentiation and its expression is the diagnostic hallmark for conventional chordoma [111] . Immunohistochemistry positivity for brachyury is strongly recommended to confirm diagnosis. Dedifferentiated chordomas may lose brachyury expression. Genomic alterations of brachyury genes (duplications) are also frequent in familial and sporadic forms along with activating mutations of the PI3K gene-activated mutations [112] .
Due to the rarity and long natural history of the disease, the level of evidence available for more common tumour types is currently beyond reach for chordoma. In fact, only a few phase II trials are available and most published data are from case series and/or retrospective. Chordoma management needs to be carried out at referral centres and/or referral networks, with a multidisciplinary team including expert pathologists and radiologists, surgeons familiar with musculoskeletal tumours and site of surgery, expert radiation oncologists with access to hadron facilities, dedicated medical oncologists and a palliative care team. All diagnostic and therapeutic procedures should be discussed in a multidisciplinary expert team.
MRI is the best modality for local staging. CT scan should be used in the case of diagnostic doubt. Chordoma should be differentiated from benign notochordal lesions and, if radiological appearance is typical for these, biopsy is not recommended unless the lesion changes over time [113] . Preoperative core-needle biopsy is recommended as for sarcoma of the bones. The biopsy track needs to be included in the surgical resection. In the case of skull base chordoma, preoperative biopsy can be avoided in selected cases.
Tumour location is the most relevant variable to define the primary tumour treatment.
The quality of surgical margins is the most important prognostic factor. En bloc R0 resection is standard treatment [IV, B], when it is feasible and sequelae are acceptable/accepted by the patient, with an expected 5-year recurrence-free survival of 50%. For sacral chordoma, surgery should definitely be offered as the first choice if the chordoma arises from S4 and below. Surgery should always be discussed in the context of other alternatives for tumours originating above S3, since surgery is always followed by important neurological sequelae. Surgery is the primary standard choice for tumours originating from S3, especially if the preservation of S2 roots is possible, as it may result in some neurological recovery (40% of cases) [115] [116] [117] .
If en bloc R0 resection is not feasible, definitive radiotherapy alone should always be considered as a valid alternative [III, B] [118] [119] [120] [121] . Local relapse has extremely poor survival rates and local control is rarely achievable. Supportive care should be incorporated into the treatment from the beginning.
For skull base and upper cervical tract chordoma, R1-R2 surgery plus high-dose radiotherapy is the treatment of choice [114, 118, 119] .
Hadrons, i.e. high-dose protons or carbon ions, are superior to photons physically and in terms of sparing irradiation of non-target lesions, although no randomised trial is available at present to assess the benefit of hadrons compared with photons in chordoma. Since hadrons allow lower doses to be given to normal tissues, they should be considered the treatment of choice. Advanced technology photons could be used in the case of unavailability or non-accessibility of protons and ions, and every time they show similar dose distribution to the target and critical structures. Due to the relative radiation resistance of chordomas, a high-dose up to at least 74 GyE in conventional fractionation (1.8-2 GyE) for photon and proton therapy is required [101, 120, 121] .
Indications for definitive radiotherapy include unresectable disease, inoperable patients and neurological impairment not accepted by the patient. Radiotherapy should be considered in the case of R2 or R1 resections. A randomised study comparing proton beam therapy and surgery is ongoing (NCT02986516). The use of adjuvant/neoadjuvant radiotherapy needs to be discussed with the single patient and prospective studies encouraged.
In the case of local relapse, the choice of treatment can include surgery and/or radiotherapy and/or systemic treatment, balancing morbidity and quality of life.
For oligometastatic disease, surgery/radiofrequency ablations/stereotactic radiation of metastases can be considered in selected cases. Chemotherapy is inactive. An exception can be high-grade dedifferentiated chordoma, for which anecdotal responses to chemotherapy have been reported [V, C]. There is phase II evidence that imatinib or sorafenib can be beneficial in advanced chordoma in terms of progression-free survival and mainly non-dimensional tumour responses [122] , and a randomised phase II study with regorafenib is ongoing (NCT02389244); its role within the treatment strategy deserves further evaluation. However, when other treatments are no longer possible, it could certainly be considered if available. Prospective studies are ongoing. In the case of low-grade bone sarcoma, the frequency of follow-up visits may be lower (e.g. 6 months for 2 years and then annually). Late metastases as well as local recurrences and functional deficits may occur > 10 years after diagnosis and there is no universally accepted stopping point for tumour surveillance.
Follow-up, long-term implications and survivorship
In ES, where osseous metastases are likely, isotope bone scanning can be used but should be weighed against the additional radiation exposure, particularly in younger patients. More modern techniques (e.g. PET or whole-body MRI) are increasingly being adopted into routine practice, but require further evaluation in clinical trials. This is a general priority for all cancers.
Importantly, there is lack of consensus on this chapter within this panel, taking into consideration the specific risk and performance of systematic imaging follow-up regarding the median and long-term risk of second cancers. Some panellists propose 6 monthly follow-up. Some propose interruption of systematic follow up at 5 years, while others maintain it beyond 10 years. National guidelines may also be different across countries [123] . The lack of consensus and the very limited number of prospective trials point to the need to generate prospective clinical trials on this topic in the future.
It is important to evaluate the long-term toxic effects of chemotherapy, surgery and radiotherapy for cured patients given the incidence of late complications. Monitoring for late effects should be continued for > 10 years after treatment, depending on the chemotherapy protocol and radiation used and in conjunction with late effects services when available. Long-term cardiac evaluation is of major importance since it has been shown that deterioration of cardiac function can still occur decades after anthracycline treatment [123, 124] . Table 2 . Levels of evidence and grades of recommendation have been applied using the system shown in Table 3 . Statements without grading were considered justified standard clinical practice by the experts. 
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Figure 2. General therapeutic strategy for the three most frequent bone sarcomas
BuMel, busulfan-melphalan high-dose chemotherapy consolidation; ChT, chemotherapy.
